Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.

Finding safe and effective treatments for chronic hepatitis C virus (HCV) infection in the elderly is of clinical interest given the comorbidities and associated polypharmacy in this population. However, the number of patients older than age 65 years enrolled into clinical trials of anti-HCV medicat...

Full description

Bibliographic Details
Main Authors:	Graham R Foster, Tarik Asselah, Sarah Kopecky-Bromberg, Yang Lei, Armen Asatryan, Roger Trinh, Neddie Zadeikis, Federico J Mensa
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0208506

Similar Items

Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
by: Shih-Jer Hsu, et al.
Published: (2019-08-01)

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
by: Cotter TG, et al.
Published: (2019-07-01)

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection
by: Teresa I. Ng, et al.
Published: (2018-08-01)

Glecaprevir and pibrentasvir combination therapy for hepatitis C virus-infected Japanese patients on hemodialysis
by: Yoshiaki Tanaka, et al.
Published: (2018-12-01)

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
by: Desmond Y. H. Yap, et al.
Published: (2020-10-01)

Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases
by: Ayumi Sugiura, et al.
Published: (2020-04-01)

Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1–6 in Brazil
by: Mario Peribañez-Gonzalez, et al.
Published: (2021-01-01)

A possible case of maculopapular eruption associated with glecaprevir/pibrentasvir treatment for chronic hepatitis C virus infection
by: Hiroka Tomiyasu, et al.
Published: (2021-08-01)

Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials
by: Tram T. Tran, et al.
Published: (2018-10-01)

Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis
by: Chao Shen, et al.
Published: (2020-12-01)

P62 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis
by: Massimo Puoti, et al.
Published: (2017-08-01)

Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir.
by: Gretja Schnell, et al.
Published: (2018-01-01)

P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure
by: Fred Poordad, et al.
Published: (2017-08-01)

Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.
by: Hsu-Heng Yen, et al.
Published: (2020-01-01)

High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy
by: Wei-Ming Chen, et al.
Published: (2020-11-01)

Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia
by: Hsuan-Wei Chen, et al.
Published: (2021-06-01)

Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study
by: Bahtiyar Yilmaz, et al.
Published: (2021-09-01)

Reply to “Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia”
by: Ming-Lung Yu, et al.
Published: (2021-06-01)

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report
by: Machiko Umemura, et al.
Published: (2021-04-01)

Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study
by: Hari V. Kalluri, et al.
Published: (2021-01-01)

Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.
by: Caroline Schmidbauer, et al.
Published: (2020-01-01)

Quantitative HBsAg: Not helpful to evaluate fibrosis in HBeAg-negative chronic hepatitis B patients
by: Dimitri Loureiro, et al.
Published: (2019-01-01)

Data mining of market information to assess at-home pork demand
by: Asatryan, Armen A.
Published: (2004)

Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older
by: Steven Flamm MD, et al.
Published: (2019-01-01)

DIFFERENCES IN USING LMS OR SOCIAL NETWORKS IN EDUCATION
by: Samvel ASATRYAN, et al.
Published: (2020-04-01)

miRNAs as Potential Biomarkers for Viral Hepatitis B and C
by: Dimitri Loureiro, et al.
Published: (2020-12-01)

Personal Assistance for Older Adults (65+) Without Dementia
by: Dr Paul Montgomery, et al.
Published: (2008-01-01)

Barriers to Receiving the Influenza Vaccine in Adults 65 Years and Older
by: Madalone, Melissa
Published: (2015)

Pneumococcal Pneumonia and Invasive Pneumococcal Disease in Those 65 and Older: Rates of Detection, Risk Factors, Vaccine Effectiveness, Hospitalisation and Mortality
by: Roger E. Thomas
Published: (2021-02-01)

Assessing the health status and mortality of older people over 65 with HIV.
by: Gina Turrini, et al.
Published: (2020-01-01)

PROTOCOL: Personal assistance for non‐demented older adults (65+) with impairments
by: Dr Paul Montgomery, et al.
Published: (2007-01-01)

Comparative study between intimate partner violence victims younger than 65 years old and older than 65 years old.
by: Ana Margarida Valente da Costa Pereira
Published: (2019)

Clinical and epidemiological characteristics of pyogenic liver abscess in people 65 years or older versus people under 65: a retrospective study
by: Jorge Peris, et al.
Published: (2017-07-01)

Lived Experiences of African Americans 65 and Older After Rural Hospital Closures
by: Mike, Derrick
Published: (2020)

Frailty and Anticoagulant Therapy in Patients Aged 65 Years or Older with Atrial Fibrillation
by: Jiapeng Liu, MD, et al.
Published: (2020-01-01)

Factors Associated with Life Satisfaction in Older Adults with Chronic Pain (PainS65+)
by: Dong HJ, et al.
Published: (2020-03-01)

Multidimensional assessment of cognitively impaired adults age 65 years of age and older
by: Walts, Nancy S.
Published: (2011)

The Study of Health Behaviors for the Elderly 65 Years and Older on Factors Associated in Taiwan
by: Hsiu-Chin Chao, et al.
Published: (2011)

Expenditure Of Home Health Care Utilization Among The Elderly 65 And Older In Taiwan
by: Chen, Chihlung, et al.
Published: (2012)

Optimal VAsopressor TitraTION in patients 65 years and older (OVATION-65): protocol and statistical analysis plan for a randomised clinical trial
by: Sangeeta Mehta, et al.
Published: (2020-11-01)